Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TYMTRAN vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TYMTRAN (pegvorhyaluronidase alfa) is a recombinant human hyaluronidase that degrades hyaluronic acid (HA) in the tumor microenvironment, reducing interstitial fluid pressure and improving drug penetration.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
FDA-approved: Treatment of metastatic pancreatic ductal adenocarcinoma (m PDAC) in combination with nab-paclitaxel and gemcitabine
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Intramuscular injection: 0.5 mg/kg body weight (maximum 25 mg per dose) administered once daily for 2 to 3 days. Oral: Not available.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; extended to 20-25 hours in hepatic impairment.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Metabolized via proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Primarily hepatic metabolism via CYP3A4, with 70% excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
95% bound to albumin and alpha-1-acid glycoprotein.
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
Volume of distribution is 0.6-0.8 L/kg, indicating moderate tissue binding.
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Oral bioavailability is 70% with food; decreased to 50% when taken with high-fat meal.
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min) or end-stage renal disease, avoid use due to increased risk of myopathy.
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B, reduce dose by 50% and monitor creatine kinase levels.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Not recommended for children under 2 years of age. For ages 2 to 12 years, 0.5 mg/kg intramuscular injection once daily for 2 to 3 days, maximum 10 mg per dose. For ages 13 to 17 years, adult dosing applies.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
No specific dose adjustment, but use with caution due to increased risk of myopathy; consider lower starting dose (0.3 mg/kg) and monitor renal function and creatine kinase levels.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
None.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Hypersensitivity reactions including anaphylaxis,Hemolytic uremic syndrome (HUS) and thrombotic microangiopathy (TMA) reported in combination therapy,Hepatotoxicity: Monitor liver function,Neutropenia: Monitor complete blood counts
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
None.
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Grapefruit juice may increase fentanyl serum concentrations and should be avoided during treatment. Alcohol consumption is contraindicated due to additive CNS depression and increased risk of respiratory depression. No other specific food interactions; however, patients should maintain a stable diet to avoid pharmacokinetic variability.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
TYMTRAN (tyrosine kinase inhibitor) is contraindicated in pregnancy. Based on its mechanism of action and animal studies, it is expected to cause fetal harm. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac and skeletal anomalies. Second and third trimester exposure may lead to fetal growth restriction, oligohydramnios, and potential fetal death. Women of childbearing potential must use effective contraception during treatment and for at least 2 weeks after the last dose.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
It is unknown whether TYMTRAN is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, women should not breastfeed during treatment and for 2 weeks after the last dose. No M/P ratio is available.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
No specific dosing adjustments have been established for TYMTRAN during pregnancy as its use is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, enhanced clearance) may theoretically reduce drug exposure, but dose modification is not recommended due to teratogenic risk. Treatment should be discontinued if pregnancy occurs.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
TYMTRAN (transmucosal immediate-release fentanyl) is contraindicated in opioid-naïve patients due to risk of fatal respiratory depression. Use only for breakthrough cancer pain in patients already on ≥60 mg oral morphine/day. Do not substitute on a mcg-to-mcg basis with other fentanyl products (differing bioavailability). Monitor for signs of excessive sedation and respiratory depression. Patients must have immediate access to naloxone. Instruct patients to place the entire tablet in the buccal cavity above a molar, not to suck or chew, and avoid swallowing.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Take TYMTRAN only for breakthrough cancer pain as prescribed.,Do not use in short-term pain such as after surgery or for headaches.,Place the tablet in the buccal pouch above a back tooth; allow to dissolve completely.,Do not suck, chew, or swallow the tablet; this leads to lower effectiveness and risk.,If two tablets are needed, place one on each side of the mouth.,Wait at least 4 hours before treating another episode of breakthrough pain.,Store out of reach of children and away from pets; accidental use may be fatal.,Keep naloxone available and ensure family members know how to use it.,Report severe drowsiness, confusion, slow heartbeat, or trouble breathing immediately.,Do not drink grapefruit juice while taking TYMTRAN (grapefruit juice can increase fentanyl levels).,Avoid alcohol and other central nervous system depressants (e.g., sedatives, tranquilizers).,Dispose of unused tablets via a drug take-back program or by flushing down the toilet.,Do not stop suddenly or change dose without consulting prescriber.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TYMTRAN vs ANEXSIA 7.5/650, answered by our medical review team.
TYMTRAN is a Opioid analgesic combination that works by TYMTRAN (pegvorhyaluronidase alfa) is a recombinant human hyaluronidase that degrades hyaluronic acid (HA) in the tumor microenvironment, reducing interstitial fluid pressure and improving drug penetration.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TYMTRAN and ANEXSIA 7.5/650 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TYMTRAN is: Intramuscular injection: 0.5 mg/kg body weight (maximum 25 mg per dose) administered once daily for 2 to 3 days. Oral: Not available.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TYMTRAN and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TYMTRAN is classified as Category C. TYMTRAN (tyrosine kinase inhibitor) is contraindicated in pregnancy. Based on its mechanism of action and animal studies, it is expected to cause fetal harm. First trimester exposu. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.